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Summary 
Background: 
Cardiovascular diseases (CVD) constitute one of the most significant causes 
of morbidity and are among the three most frequent causes of death in in-
dustrial countries. They comprise coronary heart disease (CHD), cere-
brovascular disease and peripheral artery disease (PAD).  
Cholesterol lowering pharmacological interventions (statins) have been in-
creasingly used to prevent CVD. In a previous study, the potential popula-
tion health gains from 11 years of statin use in secondary prevention in Aus-
tria were calculated. The model used was based on the efficacy of statins de-
rived from clinical studies. The results need to be verified with observed 
CVD epidemiology. 
Research question: 
The study aims to analyse whether the expected health gains from statins in 
secondary prevention of cardiovascular diseases (derived from modelling) 
can also be observed in Austrian cardiovascular disease epidemiology. 
Method: 
A literature search was conducted to identify international epidemiological 
trends of CVD and the statins’ role in these. 
Expected health gains from statins in Austria were derived from an earlier 
study.  
Austrian cardiovascular disease epidemiology was analysed descriptively 
based on administrative hospital data (as proxy for morbidity) and on mor-
tality data. Statistical tests are used to analyse the influence of statins on 
Austrian CVD mortality. 
Results: 
International trends: 
Western Europe has experienced downward trends in age-adjusted CVD 
mortality. Addressing risk factors seems to have a greater impact on the 
trend than improving treatment. However, the trend towards increasing 
prevalence of some risk factors (e.g. obesity) may offset some of the positive 
effects.  
Despite the benefits attributed to lowering cholesterol with statins, tackling 
other risk factors (e.g. smoking) and implementing specific types of treat-
ment/management (e.g. hospital resuscitation after myocardial infarction) 
has shown a greater effect on reduced mortality than the use of statins. 
Expected health gains in Austria: 
In roughly 600,000 patients who took statins between 1996 and 2006 about 
26,600 cases of MI and roughly 10,200 fatal CHDs (mostly MIs) seem to 
have been avoided or postponed. The effect on (fatal) stroke was low. More-
over, about 7,000 fewer revascularisation interventions have been estimated 
compared to not taking statins.  
 
high burden of disease 
from cardiovascular 
disease 
previous research 
evaluated potential 
health gains from 
prevention with statins 
this study asks whether 
expected health gains 
are real 
method: 
identifying international 
CVD trends in literature, 
 
expected health gains in 
Austria are contrasted 
with epidemiology 
international trends: 
decreasing CVD 
mortality 
smoking and disease 
management have 
greater influence than 
statins 
expected health gains: 
between 1996 and 2006: 
minus 26,600 MIs, 
10,200 fatal CHDs and 
7,000 revascularsations 
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However, the model demonstrated that about 68,000 CVD cases or fatal 
events and 230,000 revascularisation interventions still occurred in spite of 
statin treatment.  
Observed CVD trends in Austria: 
From the age of 50 and over, discharge rates for those who were hospitalised 
for CVD rose steadily. Discharges of MI patients rose from 21,218 in 1996 to 
37,064 in 2006 (+75 %). For angina pectoris, discharges also rose slightly, 
while in the case of stroke, data are unclear. In terms of revascularisation, 
the number of percutaneous coronary interventions (PCI) has also risen con-
siderably (from 5,506 in 1995 to 16,153 in 2005/+ 194 %), while the number 
of conducted coronary artery bypass grafting (CABG) slightly decreased. 
Absolute numbers are in any case higher for men than for women. 
Age standardized CVD mortality rate fell by 59 % between 1970 and 2005. 
The decline is similar for men and women. Twenty percent of all deaths and 
40 % of all cardiovascular deaths are due to CHD. Most of the mortality 
cases in CVD occur above the age of 65. 
Contrasting the results 
While model outputs demonstrated decreasing numbers of CVD cases and 
revascularisation procedures when statin takers were compared with those 
not taking statins, hospital discharges indicate an overall increase in CVD 
morbidity.   
On the contrary, CVD mortality rates per 100,000 person years were decreas-
ing in both the model as well as observed mortality when compared to the 
reference year 1994. The trend between model results and observed mortal-
ity is particularly consistent for reductions in CHD and MI mortality rates.  
Furthermore, the average decline in relative mortality changes per year and 
in annual mortality rates per 100,000 is stronger in the period after the 
launch of statins than before. The difference is statistically significant for 
both males and females with regard to CHD mortality overall and to MI 
mortality in particular, but not in the case of cerebrovascular deaths. 
Sensitivity analysis: 
Observed CVD mortality was contrasted with model mortality outputs ac-
cording to varying gender and age distribution of statin takers in the model. 
While CVD mortality rate reductions in model and observed mortality were 
more consistent in sensitivity analysis, CHD mortality rate reduction was 
higher in sensitivity analysis and, thus, less consistent with observed mortal-
ity.  
Discussion: 
In terms of morbidity, potential health gains from statins have been shown 
for non-fatal MI in particular. Additionally, some revascularisation interven-
tions seem to have been avoided due to statins. In contrast to the model re-
sults, hospital data showed rising numbers of discharges for MI and increas-
ing numbers of revascularisation interventions.  
Although this indicates that potential health gains from statins may be 
smaller in real-life than in clinical studies, interpretation regarding the role 
of statins is limited, as the state of hospital discharges without statins is un-
68,000 (fatal) cases 
despite statins 
observed CVD trends: 
+75% discharges after 
MI and + 194% 
administered PCIs,  
 
slight decrease in CABGs 
CVD mortality rates 
declined in both sexes 
contrasting the results: 
morbidity: health gains 
in model inconsistent 
with rising 
hospitalisation 
mortality: 
corresponding 
decreasing trends and… 
…stronger mortality 
decline after statin 
launch 
more CHD health gains 
in sensitivity analysis -> 
less correspondence 
with observed CHD 
mortality reduction 
morbidity trends in 
model and real life not 
consistent, yet… 
…role of statins unclear 
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known. Additionally, several other factors may influence hospital admis-
sions such as economic incentives, changes in disease management, aging of 
the population etc.  
With respect to mortality, mortality rate reductions in the model results and 
in observed mortality are more consistent, especially in the case of CHD 
mortality. Although it was additionally demonstrated that the decline in 
mortality was faster in the time period after the launch of statins than be-
fore, a causal relationship between the utilisation of statins and observed 
mortality changes cannot be substantiated. This is because other factors may 
also have influenced mortality as demonstrated in international studies. 
General limitations of the study are related to restricted data quality, espe-
cially regarding morbidity data and statin utilisation data, thus leaving con-
siderable room for uncertainty. 
Conclusion: 
Tentative evidence exists that statins seem to have contributed to decreasing 
CHD mortality in Austria while the benefits with respect to CHD morbidity 
and related revascularisation interventions are less explicit. Hence, repeat-
edly mentioned cost saving potentials in economic evaluations need to be 
treated with caution. 
Yet, even if mortality gains exist, several hundred thousand patients need to 
be treated life-long in order to achieve this benefit. Whether this relation is 
acceptable is subject to public discussion. 
Improving morbidity data quality and gathering detailed patient-level data 
from statin patients have been identified as top-priorities for obtaining more 
definite results. 
statin-induced mortality 
reduction more likely, 
but causal relationship 
not known 
limitation: data quality 
statin-related mortality 
reduction likely, 
morbidity and cost 
benefit less clear 
whether health gains 
are sufficient requires 
debate 
better morbidity data 
and patient-level statin 
data required 
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1 Introduction  
Cardiovascular diseases (CVD) belong to the most prevalent diseases in in-
dustrial countries. They result in high morbidity and mortality rates. CVD 
comprises several types of disease which include coronary heart disease 
(CHD), cerebrovascular disease, and peripheral-artery disease (PAD). CHD 
includes myocardial infarction (MI), stable and unstable angina (SA and 
USA) as well as other chronic heart diseases. Concerning the burden of dis-
ease, in Europe just under half of all deaths from CVD are from CHD.  
Several risk factors have been identified which seem to be associated with 
CVD. One of them is an elevated blood cholesterol level. A number of pri-
mary and secondary prevention strategies have been created which focus on 
reducing serum cholesterol. They are dominated by pharmacological inter-
ventions. The most widely used products are statins (cholesterol lowering 
drugs). They were introduced in the beginning of the 1990s and have since 
then dominated the market of cholesterol lowering drugs.   
Not only has the use of statins proven to be efficacious in clinical studies, 
statins have also been described as cost-effective in economic evaluations. 
One reason for the latter is that clinical studies have shown reductions in 
hospital interventions. Thus, some of the additional costs of statin therapy 
can apparently be offset by savings in hospital costs. Since their introduc-
tion, use of and expenditure for statins have risen dramatically. In 2000, ex-
penditure for statins in EU-15 countries and Norway already was equal to € 
4 billion and had risen to over € 20 billion between 2000 and 2004 [2]. Pre-
scription and expenditure have also increased dramatically in Austria since 
1995. 
In a previous study [3], the potential population health gains from 11 years 
of statin use in Austria were calculated by using a mathematical model. The 
model was based on the efficacy of statins in terms of cardiovascular morbid-
ity and mortality derived from clinical studies. The current study aims at 
comparing the expected health gains with the actual epidemiological trends 
in Austria in order to address the question whether expected effects can be 
confirmed by observational data.  
After defining the precise research question, the report continues with a de-
scription of the methods applied in the study (chapter 3). In chapter 4, an 
overview of international trends in cardiovascular epidemiology is pre-
sented. The research question requires taking into consideration other fac-
tors which may have influenced cardiovascular epidemiology in Austria. 
Thus, determinants of epidemiological trends identified in relevant litera-
ture and the role of statins in these trends are included this chapter. Chapter 
5 presents the expected health gains from statins generally and in Austria 
specifically by summarising the main results from clinical studies and from 
the Austrian modelling approach. In chapter 6, epidemiological CVD trends 
in Austria are described based on data sources which were available. In 
chapter 7, these results are finally contrasted with those from chapter 5 and 
complemented by a sensitivity analysis in chapter 8 in order to reach a con-
clusion on whether the expected health gains from statins can be confirmed 
by epidemiological trends in Austria. 
 
CVD: high burden of 
disease in Europe 
statins dominate 
pharmacological 
prevention 
interventions 
statins: efficacious and 
cost-effective in 
literature 
 
 
increasing prescriptions 
and expenditures  
study aims: comparing 
expected heath gains 
with observational data 
 
structure of report 
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2 Research Question 
The aim of this study is to analyse whether the expected health gains from 
statins in secondary prevention of cardiovascular diseases can also be ob-
served in Austrian cardiovascular disease epidemiology.  
In detail, the following research questions will be addressed 
1. What is the trend in cardiovascular morbidity and mortality from an in-
ternational perspective for the past twenty to thirty years; what are the 
factors behind this trend; and what role do statins play in all this? 
 
2. What are the expected population health gains from statins in second-
dary prevention since their introduction in Austria in terms of 
b Cardiovascular morbidity (myocardial infarction, angina, stroke) 
b Cardiovascular mortality (fatal coronary heart disease, fatal stroke 
with history of coronary heart disease, fatal myocardial infarction) 
b Revascularisation interventions (percutaneous coronary intervention/ 
coronary artery bypass grafting) 
 
3. What has been the epidemiological trend (particularly since the mid-
1990s) in cardiovascular disease in Austria in terms of 
b Cardiovascular morbidity (myocardial infarction, angina, stroke) 
b Cardiovascular mortality (cardiovascular disease overall, coronary 
heart disease overall, myocardial infarction, cerebrovascular disease) 
b Revascularisation interventions 
4. Can a consistency be observed between expected health gains and epi-
demiological trends? 
 
 
research questions: 
cardiovascular 
epidemiology 
international? 
expected health gains 
from 11 years of statin 
treatment in Austria? 
CVD epidemiology in 
Austria? 
consistency between 
expected and observed 
CVD trends? 
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3 Method 
The research questions are addressed via a multi-step approach described 
below. 
3.1 Analysing the International 
Epidemiological Trends in Cardiovascular 
Disease 
The first question is addressed by a literature review which is concerned 
with how the burden of CVD in general and coronary heart disease (CHD) 
in particular has developed from an international perspective. It uses a 
rough time frame of 1980 to 2000. Specific attention is paid to the role of 
statins in influencing the trends. The main focus of the review is on trends 
in Western Europe.  
The literature search was done in the PubMed database, using key terms in-
cluding ‘cardiovascular disease’, ‘coronary heart disease’, ’mortality’, ‘mor-
bidity’, ‘trends’ and ‘Europe’. The literature search does not strive to fulfil 
the criteria of a systematic review but rather attempts to present an overview 
of epidemiological patterns and trends which will serve as background in-
formation. Approximately 60 seemingly relevant articles were collected and 
read. Irrelevant articles were then discarded, leaving approximately 40 con-
taining relevant information. Useful data and information were extracted 
and summarised. Due to repetition in the literature, not all relevant articles 
were drawn upon in the final review. In addition to published articles, statis-
tics from international agencies (WHO, OECD) were searched. 
3.2 Analysing Expected Health Gains from 
Statins in Austria 
This part of the report is based on the results of a previous study [3] which 
evaluated the population health gains expected from statins in secondary 
prevention by using an adapted Markov model from the UK. Model outputs 
related to cardiovascular morbidity and mortality have been linked with 
data on Austrian statin users from 1996 to 2006 in order to estimate poten-
tial population gains in cardiovascular health.  
The methodology is described in detail in the corresponding study report 
[3]. In summary, the method involved the following steps: 
b The number of Austrian statin takers was estimated by using the 
amount of statin prescriptions for calculating the total number of pre-
scribed daily doses. These results were employed to calculate mortal-
ity adjusted annual cohorts, assuming that patients take the medica-
tion every day in the base case.   
multi-step approach 
literature review to  
identify international 
trends in CVD 
used for background 
information  
 
sources: PubMed + 
international agencies 
expected health gains 
are used from previous 
study 
summary of method: 
estimation of statin 
cohort based on number 
of prescriptions 
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b A mathematical model (Markov model) from the UK that predicts 
cardiovascular health effects from statin treatment compared to non-
medical cholesterol lowering was adapted for the Austrian context. 
The following data sources were used: 
o Disease progression in the untreated cohort was based on UK 
CHD and stroke registries 
o The probability of dying was based on Austrian life tables 
o Calculation of statin treatment effects was based on a meta-
analysis of clinical trials on statins. Relative risk reductions 
for various cardiovascular outcomes were applied 
b Model outputs for a fictitious cohort were linked to the estimated an-
nual Austrian cohorts between 1996 and 2006: The cohorts from year 
1 (1996) could benefit for 11 years whereas the last cohort (starting in 
2006) could only benefit for one year. The results from each year were 
summarised for each outcome category of interest and compared to 
the alternative of not taking statins. 
b Sensitivity analyses were conducted to test for uncertainty of the re-
sults: The influence of compliance and different age and gender dis-
tribution of statin takers on cohort sizes and potential health gains 
were evaluated 
3.3 Analysing Epidemiological Trends in 
Cardiovascular Diseases in Austria 
In order to analyse Austrian epidemiological trends in cardiovascular mor-
bidity and mortality, several data sources are used: Since there are no ‘offi-
cial’ morbidity data on a population basis available in Austria administra-
tive hospital data are used as proxy for morbidity.  
Data show the age- and gender-specific cases of discharges from patients di-
agnosed with angina pectoris, myocardial infarction (MI) or stroke as well as 
the number of revascularisation interventions with respect to percutaneous 
coronary intervention (PCI) and coronary artery bypass grafting (CABG). 
These are used descriptively to identify trends in cardiovascular morbidity.  
The following documented ICD-10 codes and the codes for specific services 
(MEL-codes) were used to define and select the diagnoses and interventions 
of interest: 
b Angina: I20  
b MI: I21-I24 
b Stroke: I61, I63, I64, I66 
b PCI: MEL-codes 6512-6514, 6520–6524, 6562 
b CABG: MEL-codes 2386, 2391, 2396, 2404 
Data which have originally been documented in ICD-9 codes have been 
transformed into ICD-10 by using official recoding tables from the Ministry 
of Health.  
estimation of health 
effects from statins 
based on adapted UK 
Markov model 
model outputs were 
linked to Austrian 
cohort sizes 
uncertainty tested in 
sensitivity analyses 
data sources for 
Austrian CVD trends:  
hospital data as proxy 
for morbidity 
ICD-10 & MEL-codes  
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Overall trends as well as gender and age specific developments will be illus-
trated. Data are case-based and not person-based. Thus, persons who were 
hospitalised more than once are counted as separate cases each time in the 
statistics, a factor which introduces some bias. 
In terms of mortality, official statistics on causes of death [4] are used to de-
scribe trends in CVD mortality in Austria for different ages and gender. In 
detail, both, overall CVD mortality (I00-I99) as well as selected subgroups of 
CVD, such as fatal CHD (I20-I25), fatal MI (I21-I22) and fatal cerebrovascu-
lar diseases (I60-I69) are addressed in the analysis. 
In addition to the description of the long-term mortality trend since 1970, a 
statistical analysis has been carried out in order to evaluate whether specific 
trends can be identified that may be correlated with the introduction of stat-
ins: 
In detail, changes in mortality rates and in relative mortality per year were 
identified for the selected groups of CVD under evaluation. An analysis was 
made whether the development from 1970 to 1998 was different from the 
trend since 1998 when statins would have been likely to have had an impact. 
1998 has been chosen because, first of all, in clinical studies Kaplan-Meier 
curves have shown a time-lag in mortality impact of at least 1.5 years [e.g. 5]. 
Second, the number of prescriptions was low at the beginning and, third, 
studies have shown that it usually takes three years from the launch of new 
drugs till their maximum impact on survival rates [6]. 
The results are demonstrated descriptively and additionally, a selected 
number of statistical tests (t-test, Wilcoxon-test) was applied to assess statis-
tical significance of the observed differences.  
For contrasting mortality outcomes in the population health model with ob-
served mortality, changes in overall CVD mortality rates, CHD mortality 
rates, MI mortality rates and cerebrovascular mortality rates (cases per 
100,000 years) based on the reference year of 1995 have been calculated.  
Since a previous report showed considerable variation in mortality outcomes 
in the population model depending on the assumptions applied for gender 
and age-characteristics in statin users [3], sensitivity analysis was conducted 
to address uncertainty in model-based mortality rate reduction.  
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4 International Trends in Cardiovascular Morbidity 
and Mortality and the Role of Statins 
4.1 Methods Used in the Literature  
This section briefly describes the sources and statistical methods used to an-
swer the question of epidemiological trends and their determinants in the 
literature published. The sources of data were varied. Mortality data from 
the World Health Organisation was used frequently [7-9]. In other studies, 
registers were used [10, 11], such as causes of death registers and hospital 
discharge registers. Other common sources are official national statistics [1, 
11-14]. Other less common sources were surveys, clinical audits, controlled 
trials and meta-analyses, social insurance data and observational studies. 
Most articles focus on the identification of CVD mortality rather than mor-
bidity trends. Much of the literature is descriptive combined with the statis-
tical method of regression analysis (e.g. Poisson or linear regression) [7, 8, 
11, 12, 15].  
To analyse the influence and effectiveness of cardiology treatments and risk 
factor changes in observed CHD mortality trends, much of the literature 
used the so-called IMPACT model [1, 10, 12-14, 16]. The model has been 
progressively developed and revised since 1996 and has been utilised in nu-
merous country-specific analyses. The model includes details of all major 
population risk factor trends (smoking, total cholesterol, hypertension, obe-
sity, diabetes, physical activity etc.) and information about the use of cardi-
ological treatments. This information is linked with the effectiveness of 
treatments and risk factor reductions based on clinical trials, meta-analyses 
and cohort studies.  
The model calculates the number of CHD deaths that would be expected in 
a later time period if the mortality rate in the base period had remained un-
changed. The number of actual deaths in the later period is subtracted from 
the number of deaths in the base period to give the number of deaths pre-
vented. Furthermore, the number of deaths prevented by each type of risk 
factor reduction and treatment is analysed. For risk factor changes, regres-
sion coefficients from MONICA (Multinational Monitoring of Trends and 
Determinants in Cardiovascular Diseases) analyses and large cohort studies 
for smoking, cholesterol and blood pressure tend to be used. The studies also 
include sensitivity analyses due to the uncertainty surrounding certain val-
ues. Overall, the IMPACT model tends to explain approximately 90% of 
CHD mortality decreases. 
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4.2 Epidemiological Trends in Western 
Europe 
4.2.1 Overall Trends  
As stated above, most of the literature addresses mortality trends, while 
morbidity is only rarely covered. The literature consistently argues that 
Western Europe has experienced downward trends in age-adjusted total 
CVD mortality since the mid-1970s. On average, age-standardised mortality 
rates for total CVD in men declined by ~50% (~1.8% per year) in the pe-
riod 1970 to 2000. The corresponding figures for women were ~60% and 
~2% [7].  
This trend is little changed by looking at different types of CVD. CHD mor-
tality in men fell by 39% from 1975 to 1995, from 163 per 100,000 to 99 per 
100,000. In women, the corresponding decline was 55% [9]. Stroke mortality 
has decreased by 60% in men and by 65% in women on average since 1970 
[7].  
Clear parallels tend to exist between Western Europe as a whole and its in-
dividual countries. However, in contrast to Western Europe, cardiovascular 
mortality in Eastern Europe has typically been higher, reaching a peak in 
the period 1990-94. This was followed by a decline in much of Eastern 
Europe including Poland, Hungary and the Baltic States [7]. The broad con-
sensus across the literature is that the decline in CVD mortality started ap-
proximately 25 years later in Eastern than in Western Europe. The decline 
in Eastern Europe has however, been faster than that in Western Europe. 
Russia is the exception, as it has experienced particularly high rates of CVD 
mortality as well as increasing CHD mortality trends. Figure 4.2-1 shows the 
trends since 1972 for selected European countries. 
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Figure 4.2-1: Age standardised death rates from CHD for men aged 35-74 in 
selected European countries 1972 - 2006 
Source: [17] 
 
In nearly all studies, CVD mortality rates are substantially lower in women 
than in men. However, this is primarily related to CHD only. For example, 
in the Ghent-Charleroi CHD study [15], the weighted sex ratio (M/F) in 
Ghent was 3.2 for total attack rates, 3.8 for non-fatal attack rates, and 2.7 for 
fatal attack rates. Similarly, in the Netherlands, the age specific incidence of 
hospitalisation for a first acute myocardial infarction (AMI) was higher in 
men than in women and increased with age, up to 90 years [18]. Also compa-
rable are figures for Denmark and Sweden, where the male/female rate ra-
tios of the incidence of first AMI are 2.28 and 2.17 respectively [19]. 
Despite this substantial disparity, CVD continues to be the leading cause of 
death in women as well as men in most industrialised countries [20]. Fifty-
five percent of all females’ deaths are caused by CVD [21]. Also, women’s 
lesser CVD risk may merely be an illusion, arising from the age-specific 
analysis used in most CVD mortality trend studies. Stramba-Badiale et al. 
[21] put forward the idea that women are not at less risk from CVD overall, 
but rather women’s CVD risk is simply delayed by 10 years.  
Some say that the recent decline in CVD mortality in Europe has been lower 
in women than in men [21]. For example, in the Netherlands, the gap be-
tween men and women at risk from dying from CHD has become smaller in 
recent years for those aged 65 years and younger [11]. This is probably the 
case in terms of absolute numbers. However, in relative terms, this seems 
unlikely to be the case, at least for Europe as a whole.  
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An analysis of the effect of socioeconomic status on CHD in Western Europe 
shows that, in the ten populations studied, CHD mortality was higher 
among those with lower socioeconomic status than those with a high socio-
economic status among men and women aged 30-59 and >60 [22]. In most of 
the countries those of lower socioeconomic status were around 50% more 
likely to die from CHD. This can be regarded as a reflection of risk factors, 
with the better educated being more likely to cut down on, for example, 
smoking and consuming unhealthy foods. Another factor could be varying 
standards of treatment, with those of lower socioeconomic status receiving 
poorer or less treatment.  
Finally, with respect to age groups, the focus on age standardised mortality 
rates masks probable variation in CVD mortality trends between different 
age groups. Also, people in older age groups are frequently excluded from 
studies. Less encouraging CVD trends among older people may be hidden as 
a result of such exclusions. The situation in North Karelia shows that CVD 
mortality has fallen less in older age groups [12]. This indicates the need for 
caution; because a decrease in the CVD mortality rate in a young age group 
cannot be extrapolated to changes of the same magnitude in other age 
groups.   
As previously mentioned, the PubMed search yielded few results for studies 
on European CVD morbidity trends: The WHO MONICA project examined 
the incidence of major coronary events in 29 populations in 16 European 
countries; however data are more than ten years old. Nevertheless, the pro-
ject has shown that the incidence of coronary events is higher in MONICA 
project populations in Northern, Central and Eastern Europe than in South-
ern and Western Europe. Results from the project have also shown that the 
incidence of coronary events is falling in MONICA project populations in 
Northern and Western Europe but not necessarily in the populations in 
Southern, Central and Eastern Europe. For example incidence rates for 
women aged 35 to 64 living in North Karelia (Finland) fell by 5.1 % per year 
between 1983 and 1992, but rose by 2.7 % per year for women living in Kau-
nas (Lithuania) [17].  
Yet, for analysing overall population morbidity trends, these results have to 
be handled with care because they only include age groups from 35 to 64 and 
may thus mask an increasing trend in morbidity in older age groups. For ex-
ample, Reitsma, Dalstra et al. [11] found an increase in hospital admissions 
due to chronic cases. While the incidence of CVD fell, chronic CVD rose by 
5.1% per year due to the longer survival of patients as a result of better 
treatment. This idea of an increasing burden is supported by projections 
outlined by Kromhout [23], who estimates that from 1994 to 2015 the num-
ber of prevalent cases of CHD and stroke will increase by 35-45% in spite of 
decreasing age-standardised mortality rates. This would be due to the aging 
of the population and a decline in case fatality in CVD patients.  
Hence, the declining CVD mortality trends do not necessarily indicate a fall 
in CVD morbidity. Where mortality is lowered by means of improved treat-
ment or risk factor reduction, morbidity may increase, as CVD patients may 
remain chronically ill or experience reoccurring illness. Thus, despite falling 
CVD mortality, the burden of CVD in Western Europe may be increasing. 
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4.2.2 Determinants of Change 
All relevant studies identify two key factors which have contributed to the 
fall in mortality from CVD, namely reductions in the prevalence of risk fac-
tors and improvements in treatments. Other influential factors such as 
changes in diagnoses are given little to no attention. 
Figure 4.2-2 below gives an indication of the relative contributions of risk 
factor changes and treatments to decreases in the CVD mortality rate, as 
identified in various countries and studies. According to figure 4.2-2, reduc-
tion in risk factors accounted for between 44 % and 76% of the decrease in 
deaths from coronary heart disease in the latter two or three decades of the 
twentieth century. The corresponding figure for treatments is 23 % to 47%. 
Thus addressing risk factors seems to have had a greater impact on CVD 
mortality rates than treatment.  
Figure 4.2-2: Explanation of the decrease in deaths from coronary disease, 1980-
2000 
Source [1] 
The mention of causally linked risk factors throughout the literature seems 
to suggest a consensus regarding their effects on CVD. They are frequently 
referred to as ‘classical risk factors’. Table 4.2-1 summarises the major risk 
factors that have been associated with CVD, although some of them (e.g. ele-
vated homocystein) are still under debate. Risk factors such as hypertension, 
elevated lipids, smoking, obesity or diabetes are suspected to account for 
some 80% of cardiovascular diseases [24]. In terms of elevated blood choles-
terol, research from the WHO highlights that over 60 % of CHD and around 
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40 % of ischemic stroke in developed countries is due to elevated blood cho-
lesterol levels [17].  
In turn, falling elevated cholesterol and reduced smoking prevalence are re-
peatedly identified as the key factors in the decrease in CVD mortality in 
Europe. Diet is frequently cited as a reason for consistently low rates of 
CVD mortality in southern Europe, where high consumption of monoun-
saturated fats such as olive oil and antioxidants in fruit and vegetables is 
common [e.g.25]. 
However, the risk factors by themselves are often poor predictors of who will 
go on to have a CVD event as Ebrahim et al. [26] have shown for blood cho-
lesterol.  
Table 4.2-1: Proven and putative risk markers for cardiovascular disease  
Proven and Putative Risk Markers for Cardiovascular Diseases 
Risk factors that are casually linked:  
Tobacco consumption  
Elevated LDL 
Low HDL  
High blood pressure  
Elevated glucose  
Physical inactivity 
Obesity 
Diet* 
Risk markers that show associations:  
Low socioeconomic status* 
Elevated prothrombotic factors: fibrinogen, PAI-1 
Markers of infection or inflammation 
Elevated homocysteine  
Elevated lipoprotein(a)  
Psychological factors (depression, proneness to anger, hostility, stress, acute 
life-events) and breakdown in social structures (loss of social support and cohe-
sion)* 
* Predisposing risk factors: A predisposing risk factor is presumed to work, at 
least in part, through an impact on other risk factors that act directly. For exam-
ple, obesity raises blood pressure, causes dyslipidemia, and increases blood glu-
cose. That some of the predisposing risk factors also have direct effects is prob-
able.  
PAI: plasminogen activator inhibitor 
Source: [27] 
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With respect to specific countries, an interesting example is Finland where a 
community-prevention program in North Karelia was implemented in 1972 
in order to change risk factors and health behaviours. From 1968-71 to 1995, 
age-standardised CHD mortality in North Karelia fell by 73%, the corre-
sponding figure for the whole of Finland was 65% [12]. Further reductions 
were observed after this period. It is estimated that of the 55% reduction in 
CHD and stroke mortality in Finland from 1972 to 1992, three quarters are 
attributable to a reduction in cholesterol (13% in men and 18% in women), 
blood pressure reductions and decreases in smoking levels [12], while only 
23% of the mortality reduction in CHD is attributable to improved CHD 
treatments [10]. Thus, the Finnish case appears to correspond with that of 
the rest of Europe, in which improvements in three key risk factors proved 
crucial. 
Similarly, in England and Wales estimates showed that approximately 60% 
of the CHD mortality decrease is attributable to risk factors, and 40% to car-
diological treatments [7]. A significant (34%) reduction in smoking led to 
48% of the reduction in CHD deaths. Blood pressure and cholesterol each 
contributed to around 10% (Table 4.2-2).  
Table 4.2-2: Deaths prevented or postponed as a result of population risk factor changes in England and Wales 
1981-2000 
Source: [28] 
 
The negative effects of low physical activity, obesity and diabetes are causes 
for concern. Figure 4.2-3 emphasises the fact that while focusing on risk fac-
tors overall has had a positive effect on CVD mortality rates, some risk fac-
tors are contributing in a negative way.  For example, in England and Wales 
between 1981 and 2000, certain risk factors developed in an adverse fashion, 
thus causing additional CHD deaths. The increasing prevalence of risk fac-
tors such as obesity, diabetes and physical inactivity have counterbalanced 
some of the positive effects of, for example, falling cholesterol and smoking. 
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Deaths Prevented or Postponed (No.) 
 
 
 
Risk factors 
% Change in 
Risk Factor 
1981-2000 
 
 
ß 
Coefficient 
Best 
Estimate 
Minimum 
Estimate 
Maximum 
Estimate 
Proportion of 
Overall Deaths 
Prevented or 
Postponed, % 
Best Estimate 
Smoking - 34.0 0.51 29,715 20,037 44,677 48.1 
Population blood pressure  -7.7 0.67 5,868 4,246 15,469 9.5 
Cholesterol  -4.2 2.46 7,900 5,284 16,692 9.6 
  Relative 
Risk 
    
Deprivation -6.6 1.24 2,126 1,063 3,189 3.4 
Physical activity -30.6 0.5 -2,662 -1,491 -3,460 -4.3 
Obesity +186.2 1.57 -2,097 -1,339 -2,587 -3.4 
Diabetes +65.6 4.24 -2,888 -2,567 -4,685 -4.7 
Total risk factor effects … … 35, 944 23,123 62,195 58.2 
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Figure 4.2-3: Explanation of the decline in CHD mortality in England and 
Wales 
Source: [28] 
 
Although a reduction in blood cholesterol seems to play a significant role in 
its effect on mortality trends, previous studies do not specify the extent the 
deaths prevented can be attributed to cholesterol lowering drugs. Also un-
clear is the role of other measures in primary and secondary prevention in 
reducing elevated blood cholesterol. 
Along these lines, Unal et al. [14] provide an overview of the roles of primary 
and secondary prevention in the reduction of risk factors. Primary preven-
tion, as shown in Table 4.2-3, was four times more effective than secondary 
prevention in the period 1981-2000. However, the amount of deaths pre-
vented by statin treatments (2,135) is considerably higher in secondary pre-
vention (1,990 or 93 %) than in primary prevention (145 or 7 %).  
With respect to cholesterol lowering, in primary prevention improved diet 
seems to have a considerably higher impact on the prevention or postpone-
ment of deaths than statin treatment. From 4,710 estimated deaths pre-
vented due to cholesterol lowering in primary prevention 4,565 (97 %) were 
attributed to diet, while only 145 (3 %) were attributed to statins. On the 
contrary, in secondary prevention, from 3,190 deaths prevented due to cho-
lesterol lowering, 1,990 (62 %) were attributed to statins compared to 1,205 
(38 %) which were attributed to improved diet. The more favourable impact 
of statins in secondary prevention is most likely a reflection of better treat-
ment uptake (Table 4.2-3). 
However, of all the measures addressing risk factors, the highest number of 
the deaths prevented can be attributed to a change in smoking behaviour in 
both primary and secondary prevention. In the former, smoking behaviour 
changes accounted for more than two thirds of all deaths prevented as op-
posed to less than 1 % due to statin treatments. In the latter, whereas 
changes in smoking behaviour accounted for 57 % of deaths prevented, the 
which effect has 
reduced blood 
cholesterol? 
statins in secondary 
prevention more 
effective than in 
primary prevention  
biggest effect from 
cholesterol lowering in 
primary prevention: 
diet, 
in secondary 
prevention: statins  
greatest impact overall: 
reduced smoking 
International Trends in Cardiovascular Morbidity and Mortality and the Role of Statins 
LBI-HTA | 2008 27 
lowering of cholesterol through the use of statins accounted for 23 % (Table 
4.2-3).   
 
Table 4.2-3: Fall in CHD mortality attributable to changes in risk factors in people with and without 
recognised CHD: England and Wales 1981-2000 
* primary prevention = in healthy people; **secondary prevention = in people with 
coronary heart disease; † all numbers rounded to nearest 5; min-max = 
minimum and maximum estimates; ‡ antihypertensive treatment was sub-
sumed in secondary prevention medication component of IMPACT model; 
source: [14] 
 
Table 4.2-4 provides an additional perspective and gives a comprehensive 
list of the treatments available for CHD which could have had an impact on 
the declining CVD mortality rates in the last few decades in England and 
Wales.  
From several treatment types available, statins have been identified to ac-
count for an absolute risk reduction for CVD deaths of 0.018 in secondary 
prevention in England and Wales. From a minimum of 2,850 deaths pre-
vented or postponed due to secondary prevention after myocardial infarc-
tion, statins have accounted for 432 (25 %). If a maximum estimate of 5,095 
deaths prevented/postponed is assumed, statins are expected to account for 
1,341 (11%). From all deaths prevented in secondary prevention, statins ac-
count for 0.7 %. Considerably more deaths prevented are attributed to Aspi-
rin or ß-Blockers. Contrary to the case for secondary prevention, in primary 
prevention statins have been estimated to account for an absolute risk reduc-
tion of 0.002 and an overall proportion of deaths prevented or postponed of 
0.2 %. 
Deaths Prevented or Postponed 
Primary prevention* Secondary prevention** 
 
 
Risk factor 
Change in 
population risk 
Factor level (%) No (min-max) † % No (min-max) † % 
 
 
Total 
Smoking :        
Overall -35 24,680 (16,935-36,420)    83 5,035 (3,100-8,255) 17 29,715 (20,035-44,675) 
Cholesterol:        
Overall -4.2 4 ,710 (3,335-10,060) 60 3,190 (1,950-6,635) 40 7,900(5,285-16,695) 
Attributable to diet  4 ,565 (3,290-9,650) 79 1,205 (645-2,455) 21 5,770 (3,935-12,105) 
Attributable to statins  145 (45-410) 7 1,990 (1,305-4,180) 93 2,135 (1,350-4,590) 
Blood pressure:        
Overall -7.7 7,235 (3,965-14,525) 93 520 (285-940) 7 7,755 (4,250-15,460) 
Secular trend  5,345 (3,125-11,740)  520 (285-940)  5,870 (3,410-12,680) 
Antihypertensive treatment  1,890 (840-2,785)  ‡  1,890 (875-3,165) 
All three major risk factors  36,625 (24,235-61,005) 81 8,745 (5 335-15 830) 19 45,370 (29,570-76,835) 
England and Wales 
from deaths prevented 
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% 
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Table 4.2-4: CHD deaths prevented or postponed by medical and surgical treatment in England and Wales 1981-2000 
Source:[28] 
 
 
 
Deaths Prevented or Postponed 
 
 
 
 
Treatment 
 
 
Patients 
Eligible 
 
 
Treatment 
Uptake 
% 
 
 
Absolute 
Risk 
Reduction 
Best 
Estimate 
Minimum 
Estimate 
Maximum 
Estimate 
Proportion of Overall 
Deaths Prevented or 
Postponed, % 
Best Estimate 
Acute  myocardial infarction 66,196  0.110 4,779 3,118 7,928 7.7 
Community resuscitation 3,045 48 0.208 799 742 958 1.3 
Hospital resuscitation 7,282 99 0.033 1,453 680 2,185 2.4 
Thrombolysis  46 0.024 1,321 493 1,636 2.1 
Aspirin  94 0.057 1,949 1,132 2,780 3.2 
Primary angioplasty  1 0.008 38 13 207 0.1 
β-Blockers  4 0.011 21 11 38 0.0 
ACE Inhibitors  19  172 47 123 0.3 
Total secondary prevention    6,899 4,587 12,670 11.2 
Secondary prevention after infarction  313,378   3,844 2,850 5,059 6.2 
Aspirin  56 0.009 1,263 641 1,991 2.0 
β-Blockers  34 0.014 969 569 1,636 1.6 
ACE inhibitors  19 0.014 442 336 1,439 0.7 
Statins  25 0.018 459 432 1,341 0.7 
Warfarin  4 0.009 100 58 233 0.2 
Rehabilitation  23 0.017 673 304 1,231 1.1 
Secondary prevention after revascularization 315,680  0.028 3,055 1,737 7,610 4.9 
Chronic angina     3,424 1,907 5,889 5.5 
       CABG surgery (1990-2000) 187,416 100 0.009 1,935 1,124 2,375 3.0 
       Angioplasty (1880-2000)  112,404 100 0.005 559 160 814 0.8 
       Aspirin in community  1,763,633 55 0.001 1,104 627 2,117 1.6 
Unstable angina  67,376   912 620 1,622 1.5 
       Aspirin and heparin   59 0.012 467 334 718 0.8 
       Aspirin alone   30 0.013 234 127 657 0.4 
       Platelet llb/lla inhibitors  48 0.007 211 158 247 0.3 
Heart failure   … 7,760 5,957 17,356 12.6 
       Hospital  34,689 62 … 4,756 4,228 11,762 7.5 
       Community 242,088 56  3,211 1,802 5,997 5.0 
Hypertension treatment  13,352,868 53 0.001 1,888 875 3,166 3.1 
 Statins for primary prevention  7,630,759 3 0.002 143 47 410 0.2 
Total treatment effects, 2000    25,805 17, 110 49,042 41.80 
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4.3 Conclusion 
Studies consistently show that Western Europe has experienced downward 
trends in age-adjusted CVD mortality. This is true for both men and women. 
The trend in Eastern European countries has started later than in Western 
Europe except for Russia where mortality rates have been increasing.  
While studies on trends in CVD mortality seem to be common, less informa-
tion on CVD morbidity trends was found. Generally favourable trends in 
CVD mortality identified in this review, however, could conceivably be 
masking less favourable trends in CVD morbidity, due to the improved 
treatments and the lowering of case fatality rates. Thus, the overall burden 
of CVD may be underestimated.  
Furthermore, many studies focus on declining CHD mortality trends. Ignor-
ing other types of CVD may lead one to under- or overestimate the overall 
burden, because other types of CVD may not show the same trends. How-
ever, while this needs to be kept in mind, the CHD trends seem to be more 
or less in line with the CVD statistics that are available, and therefore the 
inference could very well be correct that trends in al or most types of CVD 
are favourable whenever CHD trends are favourable.  
Tackling risk factors seems to have a greater impact on the downward trend 
than improving treatment. However, the trend towards increasing preva-
lence of some risk factors (e.g. obesity) may offset some of the positive ef-
fects.  
While in overall terms, primary prevention seems to have a greater impact 
on mortality reduction than secondary prevention, in the case of statins, the 
number of deaths prevented is considered higher in secondary prevention 
than in primary prevention. Yet, despite the obvious benefits that have been 
attributed to statins, focusing on other risk factors (e.g. smoking) and im-
plementing specific types of treatment/management (e.g. hospital resuscita-
tion after myocardial infarction) have shown a greater effect on mortality 
reduction than the use of statins. 
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5 Expected Gains in Cardiovascular Health from 
Statins in Austria  
5.1 The Role of Statins in the Prevention of 
CVD 
5.1.1 Efficacy in Clinical Trials 
The efficacy of statins in terms of surrogate endpoints (reduction of serum 
cholesterol) and clinical endpoints (reduction in morbidity, mortality and 
revascularisation procedures) has been evaluated in several trials.  
Although not all statin types have demonstrated significant effects for all 
relevant patient outcomes1, the meta-analysis by Ward et al. [30] has estab-
lished that overall statins in secondary prevention have significantly reduced 
the relative risk for all-cause mortality, CVD mortality, CHD mortality and 
fatal MI in clinical trials. Furthermore, relative risks have been reduced for 
nonfatal stroke, unstable angina, hospitalisation for stable angina and revas-
cularisation interventions (Table 5.5-1).  
In terms of absolute risk reduction, the greatest effect size occurred for the 
combined endpoint of CHD mortality and morbidity. Depending on the 
study, average absolute risk reduction was between 3 % (CARE study) and 
8.57 % (4S-Study) corresponding to a number-needed to treat of 34 (22.8-
95.5) and 12 (9-16.4) [30].  
The medical background on statins has been described in more detail in pre-
vious reports [3, 31]. 
 
                                                             
1 e.g. in patients with stable coronary heart disease, only the statins simvastatin and 
pravastatin showed benefits with respect to a life-prolonging effect [29]
 IQWIG. Evaluation of the effects of statin (with particular consideration of 
atorvastatin). Köln: IQWIG; 2006. 
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Table 5.1-1: Relative risks of events from meta-analyses of clinical trials 
Outcome All studies Secondary Pre-
vention CHD 
Secondary Prevention 
CVD 
All-cause mortal-
ity 
0.84 (0.78-0.90) 0.79 (0.70-0.90) 0.80 (0.71-0.90) 
CVD mortality 0.79 (0.74- 0.85) 0.75 (0.68-0.83) 0.75 (0.68-0.83) 
CHD mortality 0.77 (0.72-0.83) 0.72 (0.64-0.80) 0.72 (0.64-0.80) 
Stroke mortality 0.92 (0.74-1.14) 1.07 (0.67-1.71) 1.08 (0.67-1.72) 
Nonfatal stroke 0.75 (0.63-0.90) 0.75 (0.59-0.95) 0.75 (0.59-0.95) 
TIA 0.79 (0.68-0.91) 0.66 (0.37-1.17) 0.66 (0.37-1.17) 
Fatal MI 0.54 (0.44-0.67) 0.57 (0.45-0.72 0.57 (0.45-0.72) 
Nonfatal MI 0.70 (0.63-0.77) 0.69 (0.59-0.79) 0.69 (0.61-0.78) 
Stable angina 
(SA) 
0.59 (0.38-0.90) No data No data 
Unstable angina 
(USA) 
0.82 (0.74-0.90) 0.82 (0.72-0.94) 0.82 (0.72-0.94) 
Patients hospitali-
sed for SA 
0.88 (0.84-0.94) 0.90 (0.84-0.97) 0.90 (0.84-0.97) 
CABG 0.74 (0.67-0.82) 0.76 (0.66-0.87) 0.76 (0.66-0.87) 
PTCA 0.78 (0.67-0.90) 0.79 (0.67-0.94) 0.79 (0.67-0.94) 
CABG+PTCA 0.75 (0.70-0.81) 0.77 (0.69-0.85) 0.77(0.69-0.85) 
CHD death + 
nonfatal MI 
0.74 (0.71-0.77) 0.73 (0.68-0.80) 0.74(0.69-0.79) 
Source: Ward et al. [30]; Statistically significant results in bold 
CABG: coronary artery bypass grafting; CHD: coronary heart disease; CVD: car-
diovascular disease; MI: myocardial infarction; PTCA: percutaneous 
transluminal coronary angiography; TIA: transient ischemic attack 
5.1.2 Statin Treatment in Austria 
As has been described by Zechmeister et al. 2008 [3], statins have been re-
imbursed by the social insurance since the mid 1990s. Until 2004, reim-
bursement was restricted to secondary prevention only. The number of pre-
scriptions has risen from 432,170 in 1996 to 3,468,303 in 2006. In terms of 
statin type, simvastatin accounted for the biggest proportion of statins pre-
scribed (40%), followed by atorvastatin (28.5 %). Pravastatin and fluvastatin 
accounted for 16.7 and 11.3 % respectively whereas lovastatin (2.9 %) and 
rosuvastatin (0.5 %) played a marginal role with respect to volumes.  
Additionally, expenditure for statins has also risen notably since the mid-
1990s. In 1996, around 17 million Euros were paid for statins by the social 
insurance institutions. Expenditure peaked in 2003 when 94 million Euros 
were spent on statins.  In 2006 expenditure for statins decreased to around 
76 million Euros due to the introduction of generics. Again, simvastatin and 
atorvastatin accounted for the biggest proportion of spending, followed by 
pravastatin and fluvastatin. The cost per prescription was 39.4 Euros in 1996 
and decreased to 22.5 Euros in 2006. In relation to overall expenditure for 
pharmaceuticals in Austria, the proportion paid for statins rose from 1.2 % 
in 1996 to 4.1 % in 2002. Since then, the proportion has slightly decreased. 
In 2006 statins accounted for 2.9 % [32, 33].  
According to recently published data [34, 35], not all patients who could be 
treated with statins are prescribed the drugs. In particular, studies have 
shown that only around a third of those patients who are discharged after an 
MI are prescribed lipid lowering drugs.   
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5.2 Expected Health Gains from Statin 
Treatment in Austria 
As described in the method section (chapter 3.2), in a previous study [3], 
statin treatment has been compared with the alternative of no medical cho-
lesterol-lowering therapy in terms of cardiovascular disease outcomes. 
Model outputs from an adapted Markov model have been used to calculate 
population health gains based on the number of persons who have taken 
statins in Austria between 1996 and 2006.  
The results of the report are summarised below. They represent the esti-
mated cohort sizes in Austria as well as the population health gains which 
can be expected from statin therapy based on statin efficacy in clinical trials. 
Health gains are categorised into three groups that are, first, morbidity 
health gains (angina, MI, stroke), second, mortality health gains (fatal CHD, 
fatal MI, fatal cerebrovascular disease) and, third, reductions in revasculari-
sation interventions (PCI, CABG).  
5.2.1 Cohort Size in Austria 
Based on the number of statin prescriptions and the corresponding daily 
doses prescribed, it was estimated how many persons took statins between 
1996 and 2006 in Austria. According to the base case calculation, 36,000 per-
sons started taking statins in 1996. In 2006, there were almost three times 
more persons (108,000) starting statin therapy. Overall, there would have 
been almost 600,000 persons who had taken statins between 1996 and 2006 
including those who died. The results are subject to some uncertainty. Ap-
plying a different gender and age distribution (one that is close to the per-
sons hospitalised for an MI in Austria) resulted in a total cohort of about 
750,000 persons between 1996 and 2006.  
5.2.2 Prevalence of Angina, MI and Stroke 
In terms of stable angina (SA), the model actually predicted an increase for 
the statin group since patients who take statins remain longer in that health 
state than persons who do not take statins and progress more quickly to 
more severe health states (Figure 5.2-1). 
Furthermore, the model demonstrated that had around 36,000 persons in 
1997 taken statins, this would have resulted in 11 fewer cases of unstable an-
gina (USA) in Austria. The health gains steadily increased rising to minus 
175 fewer cases in 2007 in around 108,000 patients (Figure 5.2-1). 
In terms of MI, of the 36,000 persons who took statins in the first year, 755 
cases of MI occurred in 1997 compared with 1,354 had these persons not 
taken statins. Consequently, statin treatment resulted in 599 fewer cases of 
MI. Until 2007, the difference between taking statin and not taking the 
medication rose to 5,234 fewer MIs. However, the model also predicted that 
despite taking statins, around 7,100 MIs in 108,000 statin takers occurred in 
2007 (Figure 5.2-1). 
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Finally, the model forecasted 56 cases of stroke in patients with a history of 
CHD not on statins, as opposed to 39 stroke cases for those who did take the 
medication in 1996. Thus, strokes were reduced by 17 in the first year. In 
2007, statin treatment resulted in 239 fewer strokes in patients with a history 
of CHD. However, around 490 strokes were estimated despite taking statins 
compared to 725 strokes in the untreated cohort (Figure 5.2-1).  
Figure 5.2-1: Differences in cardiovascular health states between ‘Statin’ and 
‘NoStatin’ group (absolute numbers) 
MI: myocardial infarction;  
5.2.3 Fatal Events 
Figure 5.2-2 shows the absolute differences in the number of fatal events for 
the two treatment alternatives. While the model demonstrates that 763 pa-
tients from around 36,000 would have died of CHD without statin treatment 
in 1997, treatment reduced fatal CHD events to 539 which corresponds to 
224 fewer CHD deaths. In 2007, compared to no medication, of 108,000 es-
timated statin takers 2,061 fewer persons died because of CHD according to 
the model. However, around 4,900 died of CHD despite taking statins.  
From all CHD deaths avoided, 107 and 982 are related to MI in 1997 and 
2007 respectively.  
Furthermore, for patients with a history of CHD, the model showed a con-
siderably lower reduction of fatal cerebrovascular events than fatal events of 
CHD. In the first year of observation almost no difference between taking 
statins and not taking statins can be observed. In 2007, 26 fewer patients 
died in the statin group as compared to the group not on statins.  
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Figure 5.2-2: Difference in fatal events between ‘Statin’ and ‘NoStatin’ group 
(absolute numbers) 
cerebrov.  death: cerebrovascular death; CHD: coronary heart disease; MI: myocardial 
infarction 
5.2.4 Revascularisation 
Since revascularisation procedures are closely linked to the diagnosis of an-
gina or MI, a decrease in the occurrence of these types of coronary heart dis-
ease is believed to result in reduced numbers of revascularisation proce-
dures.  
As Figure 5.2-3 demonstrates, health gains obtained from statins result in a 
reduction of both, PCI as well as CABG in the model. Compared to the 
‘NoStatin’ group, in ‘statin takers’, 162 fewer PCIs and 110 fewer CABGs 
were performed in 1997. In 2007, 632 PCIs and 447 CABGs were avoided ac-
cording to the base case analysis in the model. However, despite statins, the 
performance of 1,800 PCIs and 1,500 CABGS was estimated for 1997 and de-
livery of 25,750 PCIs as well as 20,200 CABGs was predicted for 2007. 
Compared to health gains in MI described earlier, the number of revascu-
larisation avoided has been low overall. However, since the amount of stable 
angina increases and revascularisation interventions are also provided for 
people with stable angina, the model predicts a low overall reduction in re-
vascularisation interventions.  
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Figure 5.2-3: Difference in revascularisation interventions between ‘Statin’ and 
‘NoStatin’ group (absolute numbers) 
CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention 
 
As demonstrated in Figure 5.2-4 for the health states of angina, MI and 
stroke, health gains in the statin group are greater for males than for fe-
males. This is also the case for avoided fatal events (Figure 5.2-5) 
Figure 5.2-4: Gender specific differences for angina, MI and stroke between 
‘Statin’ and ‘NoStatin’ group (absolute numbers) 
MI: myocardial infarction, USA: unstable angina 
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Figure 5.2-5: Gender specific differences in fatal events between ‘Statin’ and 
‘NoStatin’ group (absolute numbers) 
CHD: coronary heart disease; Cerebrov. death: cerebrovascular death; MI: myocardial 
infarction 
 
In total, in around 600,000 persons who were estimated to have taken statins 
over 11 years, health benefits of around 28,600 fewer cases of either unstable 
angina, MI or stroke and roughly 6,100 more cases of stable angina were 
predicted. Furthermore, the model estimated about 10,300 avoided or post-
poned fatal CVD events (mostly fatal CHD) and around 7,000 avoided re-
vascularisation interventions. 
In other words, 21 patients needed to be treated in order to avoid/postpone 
one patient going into a CVD health state. Furthermore, 59 patients needed 
to be treated to avoid/postpone one fatal event and 86 patients needed to 
take statins to avoid one revascularisation intervention.  
Although the results suggest that quite a few patients need to be treated in 
order to gain benefits in one, the prescription of statins from 1996 to 2006 
nevertheless should have resulted in some observable population health 
gains compared to the alternative of not taking statins. This is particularly 
the case for avoided non fatal MIs and reduced CHD mortality. Further ef-
fects in regards to stroke (for those with a history of CHD), cerebrovascular 
mortality and revascularisation interventions exist but are significantly 
smaller. To what extent model outcomes are observable in Austrian CVD 
epidemiology will be addressed in the following chapter. 
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6 Epidemiological Trends in Cardiovascular 
Morbidity and Mortality in Austria 
6.1 Morbidity 
As a proxy for morbidity trends in cardiovascular diseases in Austria, ad-
ministrative hospital data that document the angina, MI and stroke cases as 
well as revascularisation interventions (PCI, CABG) will be presented in 
this chapter. When evaluating the trends, we viewed the discharge figures 
(absolute cases) recorded in the form of ICD codes for the time period be-
tween 1995 and 2005 (see chapter 3.3).   
Overall, in 2005 every eighth hospital discharge was due to cardiovascular 
disease. For men this was the primary cause for hospitalisation and for 
women the third leading cause.  From the age of 50 and over, discharge rates 
for those who were hospitalised for CVD rose steadily [36]. 
As Figure 6.1-1 illustrates, the number of patients who were discharged after 
an MI constantly rose in the 10 year period. While in 1995, there were 21,218 
MI patients, in 2005 there were 37,064 (+75 %) patients. The number of an-
nual ‘MI discharges’ was 10 % higher for men than for women.  
Figure 6.1-1: Absolute cases of MI discharges 1995-2005 
Source: hospital discharge data (LKF-Statistics); MI: myocardial infarction 
 
Age-specific data show that the number of discharges has continuously risen 
since 1995 for all age groups in both male and female patients. However, the 
highest number of discharges in female patients was in the 76 to 84 year old 
age group. Men were most often discharged after an MI between the ages of 
66 and 75 and almost just as often between the ages of 56 and 65. A higher 
number of females than males above the age of 85 were hospitalised for an 
MI. This may be due to the longer life-expectancy of and the later occur-
rence of CVD in women (Figure 6.1-2).   
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Figure 6.1-2: Absolute age and gender specific trend for MI discharges 1995-2005 
Source: hospital discharge data (LKF-Statistics); MI: myocardial infarction 
 
A similar although slightly less continuous trend can be observed in dis-
charges with the diagnosis of stable or unstable angina (Figure 6.1-3). In 
1995, 26,204 cases were documented. In 2005, the figure rose to 39,051 cases 
with women accounting for slightly more than 40 %. 
Figure 6.1-3: Absolute cases of stable and unstable angina 1995-2005  
Source: hospital discharge data (LKF-Statistics) 
 
The case of stroke is unclear. Figure 6.1-4 demonstrates that there is a sub-
stantial drop of discharges in 2001 (from 62,700 to about 41,000 cases over-
all) after which discharges remain at the lower level. This is surprising for 
two reasons: Firstly, there is no disease-related explanation for the sharp 
drop in 2001 and secondly, it seems implausible that between 1995 and 2000 
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the number of stroke-related discharges was considerably higher than dis-
charges with a diagnosis of MI.  
This indicates substantial uncertainty with respect to data quality and accu-
racy. The true reason behind the inconsistency may be a change in the pay-
ment scheme linked to changes in coding of data which resulted in different 
classification of diagnoses in patients. For that reason, stroke data are not 
used for further analysis in the report. However, since the statin analysis is 
restricted to stroke outcomes for those patients with a history of CHD only 
and the previous report has shown little health impact from statins for those 
patients omission of stroke data will not influence the following results and 
the conclusion to a great extent.  
Figure 6.1-4: Absolute cases of stroke discharge 1995-2005 
Source: hospital discharge data (LKF-Statistics) 
 
Furthermore revascularisation procedures have been analysed. Correspond-
ing to MI, administrative data on percutaneous coronary intervention (PCI) 
show that the number of PCIs has risen progressively since 1995. While in 
1995, 5,506 interventions were registered, the amount of cases rose almost 
three times to 16,153 administered interventions in 2005. Females received 
below a third of all the interventions (Figure 6.1-5).  
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Figure 6.1-5: Absolute cases of administered PCIs 1995-2005 
Source: hospital discharge data (LKF-Statistics): PCI: percutaneous coronary inter-
vention 
 
Similar to the age-specific picture for MI, PCIs have also risen in every age 
group in both male and female patients (Figure 6.1-6). However, while in 
male patients the number of PCIs per age group seems to roughly corre-
spond with the number of MIs, this is not the case for female patients. For 
females, the age group with the highest number of MIs (76 to 85 years) 
shows a comparably low number of PCIs. The number is even lower than for 
males in the same age group despite a higher number of MIs in women than 
in men in this age group. 
Figure 6.1-6: Absolute cases of administered PCIs gender and age specific 1995-
2005 
Source: hospital discharge data (LKF-Statistics): PCI: percutaneous coronary inter-
vention 
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Finally, data on the number of coronary artery bypass grafting (CABG) were 
analysed (Figure 6.1-7). In contrast to PCI, the number of CABGs has 
slightly decreased since 2000 in both men and women. In total, 4,126 CABGs 
were documented in 1995 while in 2005, the number decreased to 4,114. 
Women received around a quarter of those interventions. 
Figure 6.1-7: Absolute cases of administered CABGs 1995-2005 
Source: hospital discharge data (LKF-Statistics): CABG: coronary artery bypass graft-
ing 
 
In both, male and female patients, CABGs decreased in all age groups ex-
cept in the 76 to 85 year olds, in which the number has constantly increased. 
However, in the 66 to 75 year olds, the decrease was slightly greater in fe-
male than in male patients (Figure 6.1-8).  
Figure 6.1-8: Absolute cases of administered CABGs gender and age specific 1995-2005 
Source: hospital discharge data (LKF-Statistics): CABG: coronary artery bypass grafting 
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In contrast to absolute numbers of discharges in cardiovascular diseases, 
Leitner (2007) [36] shows that the level of age standardised discharge rates 
per 100,000 continuously rose from 1989 to 1998 but has stagnated since 
1998. Furthermore, she demonstrates that the age-standardised discharge 
rate of persons who died during hospitalisation has fallen over the last ten 
years, thus indicating an increase in those who survive a CVD event. Conse-
quently this factor has resulted in an increase in CVD morbidity. This is re-
inforced even further by demographic changes with larger cohorts moving 
into higher age-groups. 
6.2 Mortality 
For the Austrian population, total age standardised mortality rate has de-
clined sharply by 51 % since 1970. The decrease is similar for men (-51 %) 
and for women (-52 %). The decrease is linear in shape since the 1970ies ex-
hibiting no specific dynamics such as accelerations. This is true for both 
males and females [4].  
Cardiovascular disease is one of the most important causes of mortality. In 
2005, 32,636 people died from cardiovascular disease accounting for almost 
half of all deaths [36]. Age standardized mortality rate fell by 59 % between 
1970 and 2005. This trend has been particularly noticeable during the 1980s 
and since the beginning of the 21st century. The decline is similar for men 
and women. However, to what extent these figures are a result of true health 
gains or a consequence of the change from ICD-9 to ICD-10, the introduc-
tion of new death certificates and improved data quality is unclear [4]. 
Twenty percent of all deaths and forty percent of all cardiovascular deaths 
are due to CHD. Mortality caused by CHD has been reduced by 14 % since 
the period of 1988-94 and by 26 % since the period of 1978-84 [4].  
Myocardial infarction is the most significant cause of death among all 
deaths from CHD. More than 7,000 people die every year from an MI ac-
counting for almost half of all CHD deaths (53 % in men and 40 % in 
women). The standardised death rate is more than twice as high in men as in 
women. Again, mortality has decreased since 1970. Within the last ten years 
the decline was 28 % and greater in men (-30 %) than in women (-27 %) [4]. 
Similarly, fatal cerebrovascular diseases have decreased. They fell by one 
third compared to the period of 1988-94 and by 57 % compared to 1978-84. 
Nevertheless, cerebrovascular diseases account for 11 % of all deaths in Aus-
tria (8 % in men and 13 % in women) which equals more than 8,000 deaths 
per year. The death rate for men is 20 % higher than for women [4].  
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Figure 6.2-1 demonstrates the decline in the gender specific and age-
standardised mortality rates for CVD overall, as well as for CHD, MI and 
cerebrovascular diseases.  
Figure 6.2-1: Age-standardized mortality rates for different CVDs 1970-2006; 
males and females 
Source: Statistik Austria [37] 
 
Most of the mortality cases in cardiovascular disease occur above the age of 
65. The average age of CVD death was 81.9 years in 2005. Women die on av-
erage at the age of 84.9 from CVD while the average age of CVD death for 
men is 77.5. The average age of death has increased by 5.3 years and 3.7 
years for women and men respectively over the last 20 years [36]. 
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7 Contrasting the Results: Expected and Observed 
Health Gains 
In this chapter, expected population health gains from taking statins as fore-
cast by the model and described in chapter 5.2 are contrasted with the ob-
served changes in cardiovascular epidemiology in Austria (from chapter 6) 
for the period between 1995 and 2006. The aim is to analyse whether the 
model results are reflected in real-life population health. At the same time, 
the issue of model validity is addressed. In particular, this relates to the ex-
ternal validity of clinical statin studies, since the model results are strongly 
based on the efficacy of statins in randomised controlled trials. As repeat-
edly stressed, efficacy may depart from effectiveness in routine practice, par-
ticularly due to reduced compliance of patients or other influential factors 
(e.g. co-morbidity).  
Following, model outcomes and observational data in terms of cardiovascu-
lar morbidity as well as mortality are compared based on the method de-
scribed in chapter 3.3. 
7.1 Morbidity 
Contrasting morbidity results from the model and observed morbidity is 
limited to a summary of both observed data and model results.  
Changes in the absolute number of persons in the health states under 
evaluation as well as differences between taking statins and not taking stat-
ins have been presented earlier. Overall, statin treatment is expected to re-
sult in a considerable decrease in non fatal MIs and a slight decrease in re-
vascularisation interventions. On the other hand, the number of persons 
with stable angina is expected to increase in the statin group as people re-
main longer in the less life-threatening health state of stable angina. Fur-
thermore, the number of non-fatal strokes is not likely to be affected to a 
great extent when the two alternatives are compared. Figure 7.1-1 summa-
rises the outcomes. 
On the other hand, hospital discharge data have shown that aside from 
CABG, all the parameters evaluated indicate an increase in the ten year ob-
servational period from 1995 to 2005. This is particularly the case for the di-
agnoses of MI and PCI as highlighted in Figure 7.1-2.  
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Figure 7.1-1: Absolute changes in cardiovascular health states and 
revascularisation in model 
CABG: coronary artery bypass grafting; MI: myocardial infarction; PCI: percutaneous 
coronary intervention 
 
Figure 7.1-2: Absolute number of discharges with CVD diagnoses and post 
revascularisation 
CABG: coronary artery bypass grafting; MI: myocardial infarction; PCI: percutaneous 
coronary intervention 
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7.2 Mortality 
To compare mortality outcomes in the model with observed mortality, 
changes in overall CVD mortality rates and changes in mortality rates for 
specific CVD-subgroups (CHD mortality rates, MI mortality rates and cere-
brovascular mortality rates) in cases per 100,000 person years based on the 
reference year of 1995 have been calculated.  
Figure 7.2-1 presents the results of the comparison in overall CVD mortality 
rates. Based on the reference year of 1995, mortality rates (cases per 100,000 
person years) decreased in the model as well as in observational data. How-
ever, the decrease is considerably greater in observed CVD mortality than in 
the model results. While the former decreased by more than 100 per 100,000 
between 1996 and 2006 the latter fell by 40 per 100,000 in the same time pe-
riod. 
 
Figure 7.2-1: Reduction in CVD mortality rates in model and observed data 
(cases per 100,000 person years) 
CVD: cardiovascular disease 
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Figure 7.2-2: Reduction in CHD mortality rates in model and observed data 
(cases per 100,000 person years) 
CHD: coronary heart disease 
 
For MI as a subgroup of CHD, reduction in mortality rate is slightly greater 
in observed MI mortality than in the model outcomes. While observed MI 
mortality rates fell by roughly 25 per 100,000 between 1995 and 2006, MI 
mortality rates in the model outcomes dropped by around 20 cases per 
100,000 person years during the same time period (Figure 7.2-3). 
 
Figure 7.2-3: Reduction in MI mortality rates in model and observed data (cases 
per 100,000 person years) 
MI: myocardial infarction 
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On the contrary, cerebrovascular mortality rate reductions were almost neg-
ligible with respect to model outcomes while observed cerebrovascular mor-
tality showed a considerable decrease of minus 30 cases per 100,000 in 2006 
compared to 1995 (Figure 7.2-4). 
 
Figure 7.2-4: Reduction in cerebrovascular mortality rates in model and 
observed data (cases per 100,000 person years) 
 
In order to further explore the possible influence of statins on cardiovascular 
mortality trends, a statistical analysis was conducted to discover if the trend 
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an impact on population health) was significantly different from the trend 
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on average statistically significantly more (Wilcoxon-test: p = 0.012 and 
0.002 respectively) from 1998 onwards than between 1970 and 1998.  
In women the decline in death rates per 100,000 was also greater from 1998 
onwards than between 1970 and 1998, although this is not statistically sig-
nificant (Wilcoxon-test: p = 0.067). Yet, the relative decrease in death rates 
from CHD in women were on average significantly greater after 1998 than 
before 1998 (Wilcoxon-test: p = 0.026).  
In the case of myocardial infarction, age-standardised death rates per 
100,000 dropped on average by 0.5 (sd= 2.5) in the first period of observa-
tion while from 1998 onwards the average decline is 2.9 per 100,000 (sd= 
1.6). The relative differences per year were on average minus 0.7 % (sd= 3.4 
%) for the first period and minus 6.2 % (sd= 3.5 %) for the second period. 
Both variables show that the average decline was statistical significantly 
greater after 1998 than before (t-test: p = 0.011 and < 0.001 for absolute and 
relative changes respectively). 
The same pattern appears in the gender specific analysis. In males the aver-
age decrease in myocardial infarction death rates per 100,000 and the aver-
age relative decline are significantly greater in the second period than in the 
first one (t-test: p = 0.009 and < 0.001). Respectively, in women the average 
decline in death rates per 100,000 and the average relative decline are also 
statistical significantly stronger in the period from 1998 onwards than from 
1970 to 1998 (t-test: p= 0.040 and 0.003 respectively).  
The results differ slightly for cerebrovascular diseases. For the overall popu-
lation, death rates per 100,000 decreased each year on average by 2.6 (sd= 
3.7) for the first period and by 3.5 (sd= 2.7) for the second period. Relative 
changes were on average minus 2.8 % (sd= 3.8 %) and minus 7.8 % (sd= 6.9 
%) for the two periods respectively. While the difference between the two 
periods is statistically significant when relative changes are compared (t-test: 
p= 0.009) this is not the case for the differences in death rates per 100,000 
(t-test: p= 0.513). 
A gender specific analysis shows similar outcomes. In men, the average 
changes in death rates per 100,000 do not statistically differ between the two 
periods observed (t-test p= 0.396), however the relative changes declined 
significantly more in the latter period than in the former (t-test: p= 0.009). 
The same is true for women. Both variables seem to decline to a greater ex-
tent in the latter than in the former period. However, the difference in the 
reduction in death rates per 100,000 is not statistically significant (t-test: p= 
0.626) while the difference in the relative reduction is statistically signifi-
cant (t-test: p= 0.031).  
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Table 7.2-1: Mortality differences between periods 1970-1998 and 1998-2006 
CHD: coronary heart disease; Cerebrov. disease: cerebrovascular disease; MI: myo-
cardial infarction; sd.: standard deviation; p.a.: per annum 
 
 Average annual changes in mortality rates per 
100,000 person years 
Average relative changes in mortality rates  
 1970-1998 1998-2006  1970-1998 1998-2006  
 Rate/ 
100,000 
(p.a.) 
sd Rate/ 
100,000 
(p.a.) 
sd p-
value 
Relative 
changes 
(%) 
sd Relative 
changes 
(%) 
sd p-
value 
Overall mor-
tality -14.4 12.6 -12.8 8.9 0.740 -1.96 1.6 -2.6 1.8 0.690 
CHD mortal-
ity -1.6 10.8 -3.79 2.9 0.011 -0.9 6.7 -4.0 2.9 0.004 
MI -0.5 2.5 -2.9 1.6 0.011 -0.7 3.4 -6.2 3.5 0.001 
Cerebrov. 
disease -2.6 3.7 -3.5 2.7 0.513 -2.8 3.8 -7.8 6.9 0.009 
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8 Sensitivity Analysis 
In the preceding report [3] sensitivity analysis demonstrated that potential 
population health gains from taking statins are subject to considerable un-
certainty when age and gender distribution of the statin takers was varied. 
This is especially the case for non-fatal MI and fatal CHD where more cases 
were avoided in sensitivity analysis than in the base case [3].  
Consequently, sensitivity analyses with the same variation in gender and age 
distribution were also conducted to compare mortality rate reductions in 
cases per 100,000 person years (reference year 1995) between model results 
and observational data. Figures 8.2-1 to 8.2-4 illustrate these outcomes. 
Compared to the base case, differences between observed mortality rate re-
duction and model results are lower with respect to overall CVD mortality 
when a different gender and age distribution of Austrian statin taker is as-
sumed. In other words, model results in sensitivity analysis illustrate higher 
reductions in overall CVD mortality rates than it was shown in the base case 
(Figure 8.2-1).  
This is mainly due to greater reductions in CHD mortality in the sensitivity 
analysis which is demonstrated in Figure 8.2-2. In contrast to the base case, 
the model’s calculation regarding CHD mortality rate reduction correspond 
less to the observed mortality in sensitivity analysis. The latter demonstrates 
a greater reduction in CHD mortality rates in the model than in observed 
epidemiology. Yet, with respect to MI mortality, results between model out-
comes and observed mortality are more or less consistent (Figure 8.2-3).  
In terms of cerebrovascular mortality rate reduction, sensitivity analysis did 
not have a noteworthy impact on the results (Figure 8.2-4).  
Figure 8.2-1: Reduction in CVD mortality rates in model and observed data 
(cases per 100,000 person years); sensitivity analysis 
CVD: cardiovascular disease 
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Figure 8.2-2: Reduction in CHD mortality in model and observed data (cases per 
100,000 person years); sensitivity analysis 
CHD: coronary heart disease 
 
 
Figure 8.2-3: Reduction in MI mortality in model and observed data (cases per 
100,000 person years); sensitivity analysis 
MI: myocardial infarction 
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Figure 8.2-4: Reduction in cerebrovascular mortality in model and observed data 
(cases per 100,000 person years); sensitivity analysis 
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9 Discussion 
The aim of this study was to analyse whether expected health gains from 
eleven years of statin treatment in Austria (based on the evidence from clini-
cal studies) can at the same time be observed in Austrian cardiovascular dis-
ease epidemiology. To achieve this, the expected health gains in cardiovas-
cular morbidity and mortality forecast by a model that compared persons 
undergoing statin treatment to those with no medical treatment, were meas-
ured against observed cardiovascular epidemiology in Austria.  
In terms of morbidity, potential health gains in the model have been shown 
for non fatal MI in particular. The population model demonstrated that the 
statins prescribed led to an estimated reduction of up to 26,600 non-fatal 
MIs by 2007. Additionally, some revascularisation interventions seem to 
have been avoided due to statins although the reduction is small probably 
due to an increase in other CHD health states that offsets the effect.  
However, in contrast to model results, hospital discharge data have shown 
an increase in the diseases under evaluation, most significantly in MI dis-
charges. This was particularly the case for older age groups. Furthermore, 
the number of administered PCIs has risen. Only the number of CABGs fell 
slightly in the period observed.  
Thus, there seems to be no correspondence in morbidity trends between 
model results and observed cardiovascular morbidity. However, comparison 
of these two types of results is extremely limited:  
First of all, as has been demonstrated in chapter 4.2.2, many other factors 
exist that can affect the epidemiology of cardiovascular diseases. Thus, 
health gains with respect to avoided MIs due to statins may be counterbal-
anced by other determinants of cardiovascular diseases. For example, the 
model does not take into account aging of the population. While cardiovas-
cular morbidity may well be reduced in younger age groups, this is likely to 
be compensated by the aging of the population with rising morbidity in 
older age groups. Additionally, recent health survey data indicate a trend 
towards an increasing number of people who are overweight or obese, higher 
rates of smoking among women and lowering physical activity [38, 39]. 
Similar to the example of England and Wales in chapter 4.2, this may coun-
teract the positive effect from lowering cholesterol.      
Secondly, hospital admissions are influenced by incentives which may not 
necessarily be disease related but induced by economic factors (a built bed is 
a filled bed). This is particularly the case for revascularisation interventions 
where capacity for PCIs has increased considerably over the last years [40, 
41].  
Thirdly, rising numbers of cardiovascular discharges may be caused by im-
proved diagnosis and reduced out-of-hospital case-fatalities resulting in an 
increase in admission rates. Moreover, guidelines for state of the art man-
agement of cardiovascular disease have been revised over the years [42] 
which particularly influences the number of revascularisation interventions. 
Furthermore, as the case of stroke has shown, morbidity data need further 
investigation. It may be that discharge data is not a very valid source for fac-
tual epidemiology, hence under- or overestimation of the true number of 
cases in cardiovascular diseases seems likely.  
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Finally, however, it could also be the case that the model overestimates the 
true benefit. In other words, with respect to morbidity and revascularisation 
interventions, the benefit of statins in routine clinical practice could be 
lower than demonstrated in clinical studies under ideal conditions. Since we 
do not know how hospital discharges would have been affected without the 
existence of statins, this question cannot be definitely answered for the time 
being.  
Other countries have shown similar results. For instance, Majeed et al. 
(2004) [43] demonstrated that the great increase in cost and volume for pre-
scribed lipid regulating drugs in England has been associated with only a 
modest reduction in admission rates for MI between 1996 and 2002. Chang-
ing diagnostic criteria such as the use of cardiac troponin measurement have 
been mentioned as possible explanatory factors.  
In terms of mortality, base case model results correspond well with observed 
epidemiology in regards to CHD mortality rate reduction, while the results 
differ considerably with respect to cerebrovascular and overall CVD mortal-
ity rate reduction.  
The differences can be explained by the fact that the model only considered 
fatal stroke with a history of CHD while epidemiological data include all 
types of CVD mortality. Consequently, overall CVD mortality rates are ex-
pected to be lower in the model results than in observed mortality. Yet, as 
sensitivity analysis has shown, some uncertainty also exists for CHD mortal-
ity rate reduction. 
On the other hand, the comparison of observed CHD mortality between the 
period of 1970 to 1998 and from 1998 onwards has shown that mortality rate 
has decreased significantly faster in the later period than in the earlier one 
in both males and females. The difference for cerebrovascular mortality rate 
changes between the two periods observed was less clear.  
These results are consistent with the model outcomes and indicate that stat-
ins may well have had an influence on decreasing CHD mortality. However, 
no evidence seems to indicate an impact on cerebrovascular mortality. Nev-
ertheless, similar to the case of morbidity described earlier, results are not 
enough to substantiate a causal relationship between the utilisation of stat-
ins and observed changes in cardiovascular mortality. This is again because 
several other factors may have influenced cardiovascular mortality between 
1996 and 2007: 
In chapter 4.2.2, international studies were presented which showed that 
CHD deaths avoided or postponed in secondary prevention were mostly re-
lated to changes in smoking behaviour, only a quarter of prevented deaths 
were attributed to statins. Furthermore, improved treatment in acute MI has 
shown a greater influence on CHD mortality changes than statins.  
Moreover, an international study by Folino-Gallo et al. (2005) [2] concluded 
that statin use might not be a major factor in the reduction of CHD mortal-
ity. The authors had selected two countries with high variability in statin 
utilisation (Norway and Denmark) and compared their trends in CHD mor-
tality. They demonstrated that despite a two- to five-fold greater utilisation 
of statins in Norway, no obvious difference in country-specific mortality 
trends could be observed. Failed targeting resulting in underuse, overuse or 
misuse of the medication as well as discrepancies between efficacy and real 
world effectiveness were mentioned as the factors most likely explaining the 
result. 
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On the other hand, an econometric study by Lichtenberg [6] that analysed 
the launch of new drugs’ impact on longevity between 1982 and 2001 has 
shown that – after controlling for other factors such as nutrition, environ-
ment, lifestyle, income etc. – new drug launches had a positive impact on the 
probability of survival in a sample of the 52 countries analysed. Yet, the 
study addressed drugs for several types of diseases which limits the interpre-
tation for cardiovascular diseases. 
Overall, the study has several limitations: First of all, the data used provide 
only a narrow range of information. Most importantly, hospital discharge 
data are of limited use for analysing morbidity. Furthermore, aggregated 
data on statin prescription without more precise information on demo-
graphic or clinical characteristics of statin patients leaves room for consider-
able uncertainty in the analysis of potential population health gains, thus 
making a comparison between model outcomes and observational data diffi-
cult.  
Generally, the results can only very tentatively be interpreted and leave 
many questions unanswered. More precise information could be generated 
with patient-level data on statin utilisation, linked with information on their 
individual risk, compliance/continuance and outcome. Yet, without a valid 
control group, the determination of a causal relationship between addressing 
a single risk factor, such as elevated blood cholesterol, and cardiovascular 
disease outcome parameters will remain difficult. 
Future research may consider applying the IMPACT model mentioned in 
the literature to evaluate the numerous determinants of CVD mortality 
trends in Austria in more detail.   
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10 Conclusion 
Results indicate that the question regarding whether statin treatment has 
achieved the expected impact on population health can only be answered 
vaguely.  
Tentative evidence exists that statins seem to have contributed to decreasing 
CHD mortality in Austria while the expected benefits with respect to CHD 
morbidity and related revascularisation interventions are less explicit. 
Hence, repeatedly mentioned cost saving potentials in economic evaluations 
need to be treated with caution.  
On the basis of this study, further funding of statins may be justified by a 
certain likelihood of mortality health gains, but less on economic grounds. 
Yet, even if results on mortality gains are robust, several hundred thousand 
patients needed to be treated life-long in order to achieve this benefit. 
Whether this is acceptable, is subject to political and public discussion. 
Overall, the study highlights very clearly that much needs to be done to ob-
tain a better understanding of population benefits of a widely used and ac-
cepted pharmaceutical intervention. The methodological challenges of this 
are more than obvious. For extended research, the approach chosen requires 
further development. Improving morbidity data quality and gathering de-
tailed patient-level data have been identified as top-priorities and pre-
conditions for obtaining more definite results.  
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